PLoS ONE (Jan 2013)

Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.

  • Yili Xu,
  • Jiayu Zhu,
  • Li Gao,
  • Yun Liu,
  • Jie Shen,
  • Chong Shen,
  • Glenn Matfin,
  • Xiaohong Wu

DOI
https://doi.org/10.1371/journal.pone.0078206
Journal volume & issue
Vol. 8, no. 10
p. e78206

Abstract

Read online

BACKGROUND:Recent data have suggested that serum uric acid (SUA) level is positively associated with the development of type 2 diabetes (T2DM). Whether SUA is also independently associated with the development of vascular complications and mortality in T2DM is controversial. METHODS:A computerized literature search of MEDLINE, Embase and PubMed database was conducted and the odds ratio (OR) or hazard ratio (HR) for per 0.1 mmol/l increase in SUA in each study was calculated. Cochrane's Q and I(2) statistics were used to evaluate heterogeneity among studies and pooling OR and HR with 95% confidence intervals (CIs) were calculated using random-effects models and fixed-effects models. The pooled analysis was performed using Stata 10.0. RESULTS:Our search yielded 9 eligible articles (16 ORs and HRs) including 20,891 T2DM patients. Pooled estimates for the relationship suggested that each 0.1 mmol/l increase in SUA resulted in a 28% increase in the risk of diabetic vascular complications and a 9% increase in the risk of diabetic mortality. In stratification-analysis, the positive relationship between SUA and vascular complications remained significant irrespective of mean age, adjustment for metabolic variables and medications. However, it was inconsistent in different populations (significantly positive in the Asian but not in Australian and Italian population) and sample sizes (significantly positive in the relatively large sample size [≥1000] but non-significant in the small sample size [<1000]). CONCLUSIONS:Results of this meta-analysis supported elevated SUA as an independent predictor of vascular complications and mortality in T2DM patients. SUA-lowering therapies might be helpful for prevention and treatment of vascular complications in this population.